DBS in Dystonia and Other Hyperkinetic Movement Disorders.

Détails

ID Serval
serval:BIB_246214FF1285
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
DBS in Dystonia and Other Hyperkinetic Movement Disorders.
Périodique
Current Treatment Options in Neurology
Auteur(s)
Barbey A., Bloch J., Vingerhoets F.J.
ISSN
1092-8480 (Print)
ISSN-L
1092-8480
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
17
Numéro
9
Pages
373
Langue
anglais
Notes
Document Type: Review
Résumé
OPINION STATEMENT: The diagnosis and appropriate treatment of hyperkinetic movement disorders require a work up of potentially reversible metabolic, infectious and structural disorders as well as side effects of current medication. In pharmacoresistant movement disorders with a disabling impact on quality of life, deep brain stimulation (DBS) should be considered. At different targets, DBS has become an established therapy for Parkinson's disease (GPi-STN), tremor (VIM) and primary dystonia (GPi) with reasonable perioperative risks and side effects, established guidelines and some clinical and radiological predictive factors. In contrast, for other hyperkinetic movement disorders, including secondary dystonia, Gilles de la Tourette, chorea and ballism, only few data are available. Definite targets are not well defined, and reported results are of less magnitude than those of the recognized indications. In this expanding therapeutical field without worked out recommendations, an individual approach is needed with DBS indication assessment only after rigorous multidisciplinary scrutiny, restricted to expert centres.
Pubmed
Web of science
Création de la notice
05/10/2015 12:43
Dernière modification de la notice
20/08/2019 13:02
Données d'usage